Lumos Diagnostics Holdings Limited
Lumos Diagnostics Holdings Limited
Your view on LDX.AX
Overview
What the company does, where it operates, and who runs it.
About Lumos Diagnostics Holdings Limited
- Industry
- Medical - Specialties
- Sector
- Healthcare
- CEO
- Douglas Ward
- Headquarters
- Suite 2, Level 11, 385 Bourke Street, Melbourne, VIC, AU
- Industry
- Medical - Specialties
- Sector
- Healthcare
- CEO
- Douglas Ward
- Headquarters
- Suite 2, Level 11, 385 Bourke Street, Melbourne, VIC, AU
Lumos Diagnostics Holdings Limited develops, manufactures, and commercializes point-of-care diagnostic products for diagnosis and management of infectious diseases in the United States. The company’s products include FebriDx, a point-of-care diagnostic test for detecting and differentiating viral and bacterial respiratory infections; and ViraDx, a three-in-one point-of-care test for influenza A, influenza B, and COVID-19. It also provides assay development and manufacturing services for point-of-care tests and proprietary digital reader platforms. Lumos Diagnostics Holdings Limited was incorporated in 2018 and is based in Carlsbad, California.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks the stock is worth vs. the current price.
FRC's fair value estimate for Lumos Diagnostics Holdings Limited, and the rating behind it. LDX.AX last traded at AUD 0.13; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Lumos Diagnostics Holdings Limited. Starting points for Lumos Diagnostics Holdings Limited: EPS -AUD 0.02, beta 0.55 — an Medical - Specialties name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Lumos Diagnostics Holdings Limited. Lumos Diagnostics Holdings Limited does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Lumos Diagnostics Holdings Limited. Trailing twelve-month EPS for Lumos Diagnostics Holdings Limited stands at -AUD 0.02. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Lumos Diagnostics Holdings Limited. Lumos Diagnostics Holdings Limited has reported as a listed company since 2021. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Lumos Diagnostics Holdings Limited valued side by side against its closest peers. Lumos Diagnostics Holdings Limited is measured against Medical - Specialties peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
Which funds and firms own the stock.
Which institutions hold Lumos Diagnostics Holdings Limited, and how their positions are changing. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
Buying and selling by Lumos Diagnostics Holdings Limited executives and directors. Shares of Lumos Diagnostics Holdings Limited have traded between AUD 0.08 and AUD 0.33 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
Senate Trading
U.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Lumos Diagnostics Holdings Limited. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely.
House Trading
U.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Lumos Diagnostics Holdings Limited. Representatives' reported transactions in this security, shown next to the company's fundamentals.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Lumos Diagnostics Holdings Limited. Coverage tracks Lumos Diagnostics Holdings Limited within Medical - Specialties (Healthcare). Press releases and market coverage, newest first.